Clinical Trials Arena on MSN3d
AstraZeneca reports positive outcomes from trial of Imfinzi
This perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel ...
Fierce Pharma6d
AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit for Imfinzi in early stomach cancer
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
BioSpace5d
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
MedPage Today1h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown Continues
The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
PMLive6d
AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
GlobalData on MSN9d
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC
AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.
AstraZeneca announces MATTERHORN trial results
Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
AstraZeneca's Imfinzi gets recommended for fresh EU approval
AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...
Medical Dialogues9d
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
Benzinga.com6d
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...